Navigation Links
BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
Date:8/19/2007

WOBURN, Mass., Aug. 15 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that it has appointed Dr. Thaddeus Pullano, 53, as Vice President of Quality Assurance.

(Photo: http://www.newscom.com/cgi-bin/prnh/20070815/NYW022 )

Previously, Dr. Pullano served as the Vice President of Quality Systems for Acambis from 2003 to 2007. In this role, he was responsible for all aspects of Quality Systems, including oversight of vaccine manufacturing and clinical quality assurance. Prior to joining Acambis, Dr. Pullano was responsible for quality assurance at Transkaryotic Therapies as the Company transitioned from R&D to manufacturing operations. He has also held a number of positions in quality assurance at Wyeth Vaccines. Dr. Pullano holds a Ph.D. in Biochemistry from the University of Southern California and a BS in Biochemistry from the State University of New York at Binghamton.

Philip Astley-Sparke, President & CEO of BioVex Inc, said:

"Thad has direct and extensive experience with quality systems supporting the manufacture and release of biologics for clinical trials and commercial sale. He becomes part of the core team dedicated to moving our Woburn manufacturing facility, which will supply Phase III and launch grade material, towards operational status."

About BioVex

BioVex is a privately held biotechnology Company based in Woburn. MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

BioVex's lead cancer program, OncoVEX(GM-CSF), is an oncolytic virus that selectively destroys tumor cells accompanied by the induction of a systemic immune response. OncoVEX(GM-CSF) is currently completing a Phase II clinical trial for melanoma and Phase I/II clinical trials for head & neck cancer and pancreatic cancer. Preliminary data from these studies has been very encouraging demonstrating OncoVEX(GM-CSF) has the potential to treat both local and metastatic disease. The Company is currently preparing for an initial registration study in melanoma where multiple responses have been demonstrated in an ongoing Phase II trial testing OncoVEX(GM-CSF) as stand alone therapy in patients with stage IIIc and stage IV metastatic disease.

The Company's second program is a vaccine for genital herpes, ImmunoVEX(HSV2), which provides complete protection in animal models of the disease. A Phase I study with ImmunoVEX(HSV2) is scheduled to initiate later this year.

For more information visit the company's website at http://www.biovex.com.


'/>"/>
SOURCE BioVex

Copyright©2007 PR Newswire.

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... According to a recent report ... do not have negative short- or long-term effects on benthic communities. , ... (PCBs) located at the Puget Sound Naval Shipyard & Intermediate Maintenance Facility in ...
(Date:6/26/2017)... ... 26, 2017 , ... Third Wave Bioactives, LLC announces the addition of Brett ... new business development and ensuring quality customer experience. , Brett brings to ... in technical, marketing and sales roles. “Brett’s background working with customers and eye for ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... solutions provider, announced the latest version of LimitLIS®, its rapidly growing Laboratory Information ... speed up user adoption, ensure installation integrity, and provide more customization options. Each ...
(Date:6/22/2017)... NC (PRWEB) , ... June 21, 2017 , ... ... for attracting and hiring top executive talent in the life sciences industry, today ... and Manufacturing company. The partnership takes full advantage of Beaker’s expertise in ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
Breaking Biology News(10 mins):